Update on risankizumab for the treatment of moderate to severe psoriasis.
Update on risankizumab for the treatment of moderate to severe psoriasis.
复制标题
risankizumab 用于治疗中度至重度银屑病的最新进展。
DOI：
10.1080/14712598.2020.1822813
复制
发表时间：
2020
影响因子：
4.6
通讯作者：
Al-Janabi A
中科院分区：
文献类型：
--
作者：
Al-Janabi A
银屑病的治疗前景是不断变化的。Risankizumab是最新批准的生物制剂，也是目前批准的三种靶向白细胞介素-23（IL-23）p19亚基的生物制剂之一。越来越清楚的是，不同的生物制剂在其疗效，有效性和安全性方面各不相同，突出表明有必要了解哪些患者和在何种情况下使用每种药物。Areas coveredThis article summarizes original clinical trial data，and reviews in more detail recent post-marketing studies and meta analysis that differentiate risankizumab from other biologics.它还简要探讨了risankizumab在治疗其他免疫介导的炎症性疾病的证据。专家意见risankizumab是一种治疗中重度斑块状银屑病的高效生物制剂。最近的risankizumab开放标签扩展数据显示持续治疗反应至第136周。间接比较表明IL-17抑制剂起效更快，但与Riskinumab的头对头比较显示在第16周时非劣效性，在第52周时优于Risankizumab。Risankizumab的耐受性非常好，IMMhance试验的数据表明，Risankizumab可用于潜伏性结核病患者，无再活化风险。
IntroductionThe therapeutic landscape for psoriasis is ever-changing. Risankizumab is the newest approved biologic and one of three currently licensed that targets the p19 subunit of interleukin-23 (IL-23). It is increasingly clear that different biologics vary in their efficacy, effectiveness, and safety profiles, highlighting that there is a need to understand for which patients and in which circumstances to use each drug.Areas coveredThis article summarizes original clinical trial data, and reviews in more detail recent post-marketing studies and meta-analyses that differentiate risankizumab from other biologics. It also briefly explores the evidence for risankizumab in the treatment of other immune-mediated inflammatory diseases.Expert opinionRisankizumab is a highly effective biologic for the treatment of moderate-to-severe plaque psoriasis. Recent open-label extension data for risankizumab shows sustained treatment responses to week 136. Indirect comparisons suggest IL-17 inhibitors have a faster onset, though head-to-head comparison with secukinumab shows non-inferiority at week 16 and superiority of risankizumab at week 52. Risankizumab is very well tolerated and data from the IMMhance trial suggests that risankizumab can be used in patients with latent tuberculosis without risk of reactivation.